VIDEO: Baseline laxative use does not affect Relistor outcomes in opioid-induced constipation
Click Here to Manage Email Alerts
In this video exclusive, Qi T. Yu, DO, from Loma Linda University Health, discussed how laxatives at baseline impacted the outcomes of subcutaneous Relistor in patients with advanced illness and opioid-induced constipation.
Yu presented the research at the Annual Regional Anesthesiology and Acute Pain Medicine Meeting.
“In patients with advanced illness and opioid-induced constipation, the use of [Relistor (methylnaltrexone, Salix Pharmaceuticals)] was really helpful because it increased the proportion of patients [who] were able to have a spontaneous bowel movement within 4 hours and 24 hours when they are not able to have that spontaneous bowel movement with a baseline laxative use,” she said.
Yu noted baseline laxative use did not affect the use of methylnaltrexone itself. Methylnaltrexone did not reduce efficacy of opioids and did not cause any adverse events.
Collapse
Yu QT et al. Poster 1667. Presented at: Annual Regional Anesthesiology and Acute Pain Medicine Meeting; May 13-15, 2021; Lake Buena Vista, Florida.
Read more about
Click Here to Manage Email Alerts